Codice QR

Real-world efficacy, safety, and clinical outcomes of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: The Turkey experience experience

Background/Aims: mbitasvir/paritaprevir/ritonavir (OMV/PTV/r) ± dasabuvir (DSV) ± ribavirin (RBV) combination has demonstrated excellent rates of sustained virologic response (SVR) and a very good safety profile in patients with the chronic hepatitis C virus (HCV) genotype 1 or 4 infections. We aime...

Descrizione completa

Salvato in:
Autori principali: Bilgehan Aygen, Neşe Demirtürk, Orhan Yıldız, Mustafa Kemal Çelen, İlhami Çelik, Şener Barut, Onur Ural, Ayşe Batırel, Reşit Mıstık, Funda Şimşek, Ali Asan, Gülden Ersöz, Nesrin Türker, Hüseyin Bilgin, Sami Kınıklı, Faruk Karakeçili, Gökmen Zararsız, The Study Group for Viral Hepatitis of the Turkish Society of Clinical Microbiology and Infectious Diseases*
Natura: Artigo
Lingua:Inglês
Pubblicazione: Turkish Society of Gastroenterology 2020-04-01
Serie:The Turkish Journal of Gastroenterology
Soggetti:
Chronic hepatitis C
HCV genotypes 1 and 4
ombitasvir
paritaprevir
dasabuvir
real-world effectiveness
Accesso online:https://turkjgastroenterol.org/index.php/tjg/article/view/3574
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi